AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29701875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate time point candidate surrogate outcomes
Number of subjects: 0
Study 29701875 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (dengue vaccine)
Number of subjects: 0
Study 26547659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% rhFGF‐2
Number of subjects: 328
Study 24187095 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 449
Study 24187095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 24187095 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 449
Study 21745060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size of 2
Number of subjects: 0
Study 21745060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size of 3
Number of subjects: 0
Study 21745060 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size of 4
Number of subjects: 0
Study 21745060 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19840650 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA + 2.5% NaOCl (n = 30)
Number of subjects: 80
Study 19840650 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% maleic acid + 2.5% NaOCl (n = 30)
Number of subjects: 80
Study 19840650 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (n = 20)
Number of subjects: 80
Study 17057048 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose TIV (n = 222)
Number of subjects: 444
Study 17057048 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose TIV (n = 222)
Number of subjects: 444
Study 15588236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol replacement (A)
Number of subjects: 15
Study 15588236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (B)
Number of subjects: 15
Study 15588236 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 15
Study 10908094 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockade
Number of subjects: 0
Study 10908094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9240642 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative inguinofemoral radiation therapy (Group 1, 65 patients)
Number of subjects: 135
Study 9240642 — intervention group
Group type: COMPARATOR
Intervention: No inguinofemoral radiation therapy (Group 2, 70 patients)
Number of subjects: 135
Study 8252455 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (2 mg/kg, i.v.)
Number of subjects: 52
Study 8252455 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 52
Study 3535686 — intervention group
Group type: EXPERIMENTAL
Intervention: Active slow release theophylline (Slo‐phyllin)
Number of subjects: 0
Study 3535686 — intervention group
Group type: COMPARATOR
Intervention: Placebo slow release theophylline
Number of subjects: 0
Study 31758195 — intervention group
Group type: COMPARATOR
Intervention: Colistin monotherapy
Number of subjects: 214
Study 31758195 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin-meropenem combination therapy
Number of subjects: 214
Study 30671682 — intervention group
Group type: EXPERIMENTAL
Intervention: Game Plan (GP) plus standard post-test counseling (SPC)
Number of subjects: 40
Study 28292338 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (CH) paste
Number of subjects: 40
Study 28292338 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (CH) paste plus 1.0 percent chlorhexidine (CHX)
Number of subjects: 40
Study 25712760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Prodentis (one tablet every 24 hours for 30 days)
Number of subjects: 34
Study 25712760 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered after probiotic treatment for 6 months)
Number of subjects: 34
Study 24449961 — intervention group
Group type: COMPARATOR
Intervention: No Testimonial Group
Number of subjects: 5498
Study 24449961 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffiliated Testimonial Group
Number of subjects: 5498
Study 24449961 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliated Testimonial Group
Number of subjects: 5498
Study 21771281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (starting dose 10 mg, titratable to 5 mg or 20 mg after 4 weeks)
Number of subjects: 145
Study 21771281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 145
Study 21771281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 19811584 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 60
Study 19811584 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 60
Study 16923005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) in patients with prior RVAP (Group A)
Number of subjects: 98
Study 16923005 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in patients without prior RVAP (Group B)
Number of subjects: 98
Study 16923005 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic response to CRT in patients with prior RVAP (Group A)
Number of subjects: 98
Study 16923005 — intervention group
Group type: COMPARATOR
Intervention: Echocardiographic response to CRT in patients without prior RVAP (Group B)
Number of subjects: 98
Study 14698860 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of methylprednisolone
Number of subjects: 0
Study 14698860 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 11742338 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of the external branch of the superior laryngeal nerve (EBSLN) in group A (137 patients) with superior thyroid artery ligation after identification of EBSLN.
Number of subjects: 289
Study 11742338 — intervention group
Group type: COMPARATOR
Intervention: Surgical approach in group B (152 patients) with separate ligation of the superior thyroid artery's branches close to the gland.
Number of subjects: 289
Study 11742338 — intervention group
Group type: EXPERIMENTAL
Intervention: Phoniatric evaluation with videostrobolaryngoscopy and spectrographic examination in both groups.
Number of subjects: 289
Study 9280170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-fat (HC) diet
Number of subjects: 11
Study 9280170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate (HF) diet
Number of subjects: 11
Study 9280170 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 11
Study 8339033 — intervention group
Group type: EXPERIMENTAL
Intervention: Auriculo‐acupuncture plus needle embedding in Heart acupoint
Number of subjects: 12
Study 8339033 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-point)
Number of subjects: 12
Study 3524436 — intervention group
Group type: EXPERIMENTAL
Intervention: BW942C
Number of subjects: 134
Study 3524436 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX
Number of subjects: 134
Study 3524436 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BW942C and TMP-SMX
Number of subjects: 134
Study 31903980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bed massage
Number of subjects: 28
Study 31903980 — intervention group
Group type: COMPARATOR
Intervention: Resting (control group)
Number of subjects: 28
Study 29370942 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining apical patency (AP)
Number of subjects: 320
Study 29370942 — intervention group
Group type: COMPARATOR
Intervention: Nonapical patency (NAP)
Number of subjects: 320
Study 29370942 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic consumption
Number of subjects: 320
Study 27663256 — intervention group
Group type: EXPERIMENTAL
Intervention: WIC Fresh Start (WFS) nutrition education intervention
Number of subjects: 744
Study 27663256 — intervention group
Group type: COMPARATOR
Intervention: Control group (WIC participants nationwide)
Number of subjects: 744
Study 27663256 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures developed for the study
Number of subjects: 744
Study 24108237 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 282
Study 24108237 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg/day)
Number of subjects: 282
Study 24108237 — intervention group
Group type: COMPARATOR
Intervention: Control (Amlodipine monotherapy)
Number of subjects: 282
Study 22287494 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐TCP
Number of subjects: 14
Study 22287494 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP/β‐TCP
Number of subjects: 14
Study 20332721 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injection in triceps surae muscles
Number of subjects: 22
Study 20332721 — intervention group
Group type: COMPARATOR
Intervention: Phenol nerve block of the tibialis posterior nerve
Number of subjects: 22
Study 20332721 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 22
Study 18164245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolomirole (5 mg b.i.d.)
Number of subjects: 1000
Study 18164245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 18164245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolomirole
Number of subjects: 1000
Study 18164245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolomirole and Placebo
Number of subjects: 1000
Study 17051490 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (750 mg twice daily) + Artesunate (100 mg twice daily)
Number of subjects: 100
Study 17051490 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1000 mg once daily) + Artesunate (200 mg once daily)
Number of subjects: 100
Study 17051490 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg 3 times daily) + Quinine (10 mg/kg 3 times daily)
Number of subjects: 100
Study 17051490 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (750 mg twice daily) + Quinine (10 mg/kg twice daily)
Number of subjects: 100
Study 17051490 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate combinations
Number of subjects: 100
Study 17051490 — intervention group
Group type: COMPARATOR
Intervention: Quinine cohorts
Number of subjects: 100
Study 12743434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 669
Study 12743434 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole MUPS 40 mg
Number of subjects: 669
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of cyclophosphamide in standard risk patients (trial 58831)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of radiotherapy in medium- and high-risk patients (trial 58832)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-dose cytarabine with high-dose methotrexate during interval therapy (trial 58881)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 6-mercaptopurine iv during maintenance (trial 58881)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli asparaginase (trial 58881)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte counts >100 x 10(9)/l, specific genetic abnormalities, poor initial response to steroids, high level of minimal residual disease (trial 58881)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event-free survival (EFS) rates at 6 years (trial 58831/32)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event-free survival (EFS) rates at 10 years (trial 58831/32)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of isolated CNS relapse at 6 years (trial 58831/32)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of isolated CNS relapse at 10 years (trial 58831/32)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall EFS rate at 8 years (trial 58881)
Number of subjects: 0
Study 11187917 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of isolated CNS relapse at 8 years (trial 58881)
Number of subjects: 0
Study 9088058 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback plus fading condition
Number of subjects: 45
Study 9088058 — intervention group
Group type: COMPARATOR
Intervention: Feedback condition
Number of subjects: 45
Study 9088058 — intervention group
Group type: COMPARATOR
Intervention: Control condition (experience in making judgments without feedback)
Number of subjects: 45
Study 8466005 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 micrograms.kg‐1.min‐1 of intravenous nitroglycerin
Number of subjects: 45
Study 8466005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 3923833 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (GL)
Number of subjects: 20
Study 3923833 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide (CP)
Number of subjects: 20
Study 29422463 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush with crisscross bristles
Number of subjects: 45
Study 28071044 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/d CLA for 12 weeks
Number of subjects: 74
Study 28071044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil) for 12 weeks
Number of subjects: 74
Study 23670305 — intervention group
Group type: EXPERIMENTAL
Intervention: SBR759 (3‐, 6‐, 9‐, 12‐g/day)
Number of subjects: 63
Study 23670305 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12‐g/day)
Number of subjects: 63
Study 22581148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-posterior approach for THA
Number of subjects: 100
Study 22581148 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral approach for THA
Number of subjects: 100
Study 20607878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral nerve block
Number of subjects: 20
Study 18759356 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-101,606 (NR2B selective NMDA glutamate antagonist)
Number of subjects: 12
Study 18759356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15821528 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (80 mg daily) + Pelvic Floor Muscle Training (PFMT)
Number of subjects: 201
Study 15821528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Duloxetine + PFMT)
Number of subjects: 201
Study 15821528 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine alone
Number of subjects: 201
Study 15821528 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT alone
Number of subjects: 201
Study 15821528 — intervention group
Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 201
Study 15821528 — intervention group
Group type: COMPARATOR
Intervention: Imitation PFMT
Number of subjects: 201
Study 12555017 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stenting
Number of subjects: 0
Study 10501366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 700
Study 10501366 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 700
Study 8941813 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium alloy (Gallium alloy GF)
Number of subjects: 28
Study 8941813 — intervention group
Group type: COMPARATOR
Intervention: Amalgam (Dispersalloy)
Number of subjects: 28
Study 1681224 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting chloramphenicol (double injection on admission and 48 hours later)
Number of subjects: 528
Study 1681224 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ampicillin (8 days, 4 times a day)
Number of subjects: 528
Study 6619812 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of inactivated hepatitis B vaccine (20 micrograms) by automatic jet injection
Number of subjects: 19
Study 6619812 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections
Number of subjects: 19
Study 30920084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 80
Study 30920084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 80
Study 30920084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality (mediator)
Number of subjects: 80
Study 29120986 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (12 mg)
Number of subjects: 10
Study 29120986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27271657 — intervention group
Group type: EXPERIMENTAL
Intervention: IMHP with β‐glucan
Number of subjects: 30
Study 27271657 — intervention group
Group type: EXPERIMENTAL
Intervention: IMHP without β‐glucan
Number of subjects: 30
Study 27271657 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 24149934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration of air ions (ION: 220 ± 30 × 10(3) ions cm(‐3))
Number of subjects: 14
Study 24149934 — intervention group
Group type: COMPARATOR
Intervention: Normal room conditions (PLA: 0.1 ± 0.06 × 10(3) ions cm(‐3))
Number of subjects: 14
Study 21968360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg loading dose followed by 50 mg every 12 h)
Number of subjects: 0
Study 19793213 — intervention group
Group type: EXPERIMENTAL
Intervention: CORT (Corticosteroid injections)
Number of subjects: 39
Study 19793213 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC (Eccentric decline squat training)
Number of subjects: 39
Study 19793213 — intervention group
Group type: EXPERIMENTAL
Intervention: HSR (Heavy slow resistance training)
Number of subjects: 39
Study 17999899 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic drugs administered intraventricularly through an external ventricular drain
Number of subjects: 0
Study 17999899 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15066925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening consisting of serum CA125 alternating with TVS performed semiannually over 18 months
Number of subjects: 292
Study 15066925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer risk education
Number of subjects: 292
Study 15066925 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up telephone calls consisting of up to four reminder messages
Number of subjects: 292
Study 12418394 — intervention group
Group type: EXPERIMENTAL
Intervention: Copaxone (glatiramer acetate)
Number of subjects: 32
Study 9809092 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 90
Study 9809092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 90
Study 9809092 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml of 0.5% hyperbaric bupivacaine solution
Number of subjects: 90
Study 7534838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aprotinin (200 KIU) and prostaglandin E1 (0.01‐0.02 microgram/kg/min) during cardiopulmonary bypass and the first postoperative day
Number of subjects: 20
Study 7534838 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group B)
Number of subjects: 20
Study 2793459 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic phases group
Number of subjects: 42
Study 2793459 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback group
Number of subjects: 42
Study 2793459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal training group
Number of subjects: 42
Study 31505302 — intervention group
Group type: EXPERIMENTAL
Intervention: Local retropharyngeal steroids
Number of subjects: 121
Study 31505302 — intervention group
Group type: COMPARATOR
Intervention: Control (no retropharyngeal steroids)
Number of subjects: 121
Study 31362883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25μg) added to bupivacaine (1mL bupivacaine 0.5%)
Number of subjects: 90
Study 31362883 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (5μg) added to bupivacaine (1mL bupivacaine 0.5%)
Number of subjects: 90
Study 31362883 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.5mL) added to bupivacaine (1mL bupivacaine 0.5%)
Number of subjects: 90
Study 28494643 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specialist palliative care
Number of subjects: 297
Study 28494643 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 297
Study 26495971 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-Machine Interface (BMI) training with robotic orthosis to move the paretic limb
Number of subjects: 32
Study 26495971 — intervention group
Group type: COMPARATOR
Intervention: Sham group with random orthosis movements
Number of subjects: 32
Study 22320714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm F; twice a day
Number of subjects: 16
Study 22320714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm; 3‐times/day
Number of subjects: 16
Study 22320714 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm; twice a day, plus the 'massage' method once a day
Number of subjects: 16
Study 22320714 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm F; twice a day
Number of subjects: 16
Study 22320714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm; 3‐times/day
Number of subjects: 16
Study 22320714 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm; twice a day, plus the 'massage' method once a day
Number of subjects: 16
Study 21490522 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine infusion at 2 μg · kg · min for 3 hrs
Number of subjects: 10
Study 21490522 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion at equivalent rate for 3 hrs
Number of subjects: 10
Study 21490522 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine infusion
Number of subjects: 10
Study 21490522 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 19515630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 45